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Abstract The recent discovery that microRNAs (miRNAs) are present in the circulation sparked interest in their use as po-
tential biomarkers. In this review, we will summarize the latest ﬁndings on circulating miRNAs and cardiovascular
disease but also discuss analytical challenges. While research on circulating miRNAs is still in its infancy, high analytical
standards in statistics and study design are a prerequisite to obtain robust data and avoid repeating the mistakes of the
early genetic association studies. Otherwise, studies tend to get published because of their novelty despite low
numbers, poorly matched cases and controls and no multivariate adjustment for conventional risk factors. Research
on circulating miRNAs can only progress by bringing more statistical rigour to bear in this ﬁeld and by evaluating
changes of individual miRNAs in the context of the overall miRNA network. Such miRNA signatures may have
better diagnostic and prognostic value.
-----------------------------------------------------------------------------------------------------------------------------------------------------------
Keywords MicroRNA † Cardiovascular disease † Diabetes † Atherosclerosis † Systems biology
-----------------------------------------------------------------------------------------------------------------------------------------------------------
This article is part of the Review Focus on: The Role of MicroRNA in Cardiovascular Biology and Disease
1. Introduction
microRNAs (miRNAs) are small non-coding regulatory molecules of
 22nt length that modify gene expression at the post-transcriptional
level by binding to the 3′ untranslated region (UTRs) of their target
messenger RNAs (mRNAs). Although the exact mechanism of
action is still unclear, it is accepted that at least in mammals
miRNAs bind through imperfect complementarity to their target
genes. Nucleotides 2–8, the so-called ‘seed region’, are thought to
be essential for this interaction, while the 3′ binding—although not
necessary—may compensate for weak seed binding.
1 Several mechan-
isms of action have been proposed for miRNA-mediated gene repres-
sion. Protein synthesis may be suppressed by inhibition of translational
initiation, mRNA degradation due to deadenylation or in rare cases
mRNA cleavage.
2–4 Evolutionary conserved, miRNAs constitute a
layer of epigenetic regulation that provides an additional control of in-
tricate processes such as cell growth, differentiation, stress response,
and tissue remodelling. They may act as buffers to absorb perturba-
tions and safeguard the robustness of biological systems. There is ac-
cumulating evidence for a role of miRNAs as key regulators in the
cardiovascular system: displaying distinct tissue expression proﬁles,
miRNAs orchestrate cardiac development, vessel wall homeostasis,
response to vascular injury, angiogenesis, and tissue repair.
5,6 Circulat-
ing miRNAs may not just represent the ‘spill-over’ of the cellular
miRNA content,
7 but may also contribute to inter-cellular signalling
and offer new insights into pathological mechanisms.
8–10 In this
review, we will focus on the potential of circulating miRNAs as bio-
markers of cardiovascular disease and discuss their potential as well
as their analytical challenges.
2. Stability and
compartmentalization of circulating
microRNAs
In a seminal paper, Mitchell et al.
11 demonstrated the presence of en-
dogenous miRNAs circulating in human plasma. The authors incu-
bated plasma samples at room temperature for 24 h, performed
repeated freeze-thaw cycles and assessed the expression of
miR-15b, miR-16, and miR-24 by quantitative PCR (qPCR). Unlike
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12 and
resistance to degradation from endogenous RNAse activity.
13,14
In contrast, rapid degradation was observed within minutes when syn-
thetic miRNAs (corresponding to Caenorhabditis elegans miRNAs
cel-miR-39, cel-miR-54, cel-miR-238) were spiked into human
plasma. Once the denaturing solution inactivated RNase activity, the
exogenous miRNAs escaped degradation. Thus, naked miRNAs are
susceptible to rapid degradation in plasma, whereas circulating
miRNAs are protected and resistant to RNase activity. The following
explanations have been proposed: Circulating miRNAs can reside in
microvesicles [exosomes, microparticles (MPs), and apoptotic
bodies (ABs)], which account for shedding of miRNAs into the circu-
lation and offer protection from RNase activity. Other studies demon-
strated that after isolation of microvesicles and subsequent high-speed
centrifugation of both cell culture medium
15,16 and plasma
10,17,18
miRNAs were still detectable in the fraction devoid of microvesicles,
suggesting the existence of non-vesicle associated miRNA-protein/
lipoprotein complexes in extracellular ﬂuids (Figure 1).
2.1 Intravesicular transport
2.1.1 miRNAs in exosomes
Exosomes are small vesicles (50–90 nm) of endocytic origin.
19,20 They
arestoredasintraluminalvesicleswithinthemultivesicularbodiesofthe
late endosome and released by fusion with the cell membrane. In re-
sponse to cell stimulation, buddingof endosomes occurs, a process de-
pendent on calcium inﬂux, calpain and cytoskeleton reorganization
21
and sphingomyelinase 2 activity (nSMase2), the rate-limiting enzyme
of ceramide biosynthesis, which controls the release of exosomes.
22
Exosomes contain substantial amounts of RNA,
23,24 including both
mRNA and miRNAs.
15,24–29 A total of 121 miRNAs were identiﬁed
in exosomes from mast cells and the expression of certain miRNAs
washigherinmicrovesiclesthanintheparentcells.
29Incontrast,select-
iveretentionofspeciﬁcmiRNAsthatarenotreleasedintotheextracel-
lular milieu was reported in cancer, implying that miRNAs can be
selectively packaged.
26
2.1.2 miRNAs in microparticles
Microparticles are larger than exosomes (.100 nm diameter), form
through plasma membrane budding and also contain miRNAs.
30,31
Blebbing of MPs from the cell membrane requires increased intracellu-
lar calcium, changes in membrane lipid asymmetry, and cytoskeleton
protein reorganization. This leads to exposure of phosphatidylserine
on the outer leaﬂet as a consequence of the calcium-dependent activa-
tionofscramblaseandﬂoppase/ABC1andtheinhibitionoftranslocase/
ﬂippase activities. Phosphatidylserine on the MP surface promotes co-
agulation
32 and servesasa recognition signal forclearance ofsenescent
and apoptotic cells.
33–36 Although MPs were initially considered ‘cell
debris’, experimental evidence suggests that MPs inﬂuence diverse bio-
logical functions.
37,38 Microparticles can transferchemokines, adhesion
molecules,receptors,andbioactivelipids.
39Dependingonthestimulus,
circulating MPs differ in their number, composition, and cell origin.
40 In
general, their numbers tend to increase in cardiovascular disease.
41–43
The presence of a miRNA pool has now been reported for MPs from a
variety of cell types including mast cells, platelets, endothelial cells
(ECs), and monocytes. Importantly, different stimuli alter the release
of miRNAs in MPs, suggesting that similar to exosomes the miRNA
export in MPs is an actively regulated process.
10
2.1.3 miRNAs in apoptotic bodies
Larger in size than MPs, ABs are generated in response to apoptotic
stimuli.
44 ABs have been implicated in tissue repair and angiogenesis
while their engulfment by phagocytes triggers the secretion of cytokines
or growth factors.
45 Microarray analysis of the miRNA content of ABs
derived from ECs highlighted the presence of a panel of miRNAs that
reﬂected its cellular origin and revealed several enriched miRNAs
compared with the cellular miRNA content.
9 miR-126 was the most
abundant miRNA in endothelial ABs. miR-126 is a key regulator of
vascular endothelial growth factor (VEGF) and ﬁbroblast growth
factor signalling in ECs through inhibition of two negative regulators of
the VEGF signalling pathway.
46,47 Deletion of miR-126 in mice resulted
in partial embryonic lethality due to loss of vascular integrity and
haemorrhages. A novel function of miR-126 residing in ABs was
reported in atherosclerosis: endothelial cell-derived ABs mediated the
induction of CXCL12 in a miR-126-dependent manner resulting in the
mobilization and incorporation of stem cell antigen-1 positive
progenitor cells to atherosclerotic plaques and a decrease in
diet-inducedatherosclerosisaswellascollar-induced plaque formation.
9
2.2 Extravesicular transport
2.2.1 miRNAs in lipoprotein complexes
In a recent study, it was proposed that high-density lipoprotein (HDL)
besides its classical role as a delivery vehicle for excess cellular
cholesterol also functions as a transporter of endogenous miRNAs.
In resemblance to artiﬁcial gene delivery vehicles, native HDL is asso-
ciated with miRNAs, acting as a carrier or depot for circulating
miRNAs in plasma and facilitating their transport and delivery to
recipient cells.
18 Highly puriﬁed HDL negative for exosomal marker
proteins was shown to be rich in small RNA molecules, 15–30
nucleotides in length, but devoid of long mRNAs. Total RNA
extracted from HDL and exosomes originating from plasma of
healthy individuals revealed that their miRNA proﬁle is distinct. A spe-
ciﬁc miRNA signature of HDL–miRNA complexes was identiﬁed in
patients with familial hypercholesterolaemia, including hsa-miR-22,
hsa-miR-105, and hsa-miR-106a.
2.2.2 miRNAs in protein complexes
Argonaute2 (Ago2) is part of the miRNA silencing complex. Ago2/
miRNA complexes were identiﬁed in cell culture media
16 and immuno-
precipitation of Ago2 from plasma recovered circulating miRNAs that
are not associated with microvesicles.
17 These stable complexes were
further characterized using size-exclusion chromatography to exclude a
contamination with microvesicles: whereas the majority of miRNAs
co-puriﬁed with Ago2 complexes, certain miRNAs, such as miR-16
and miR-92a but not let-7a, associated predominantly with microvesi-
cles. A mechanism involving cell type-speciﬁc release in either microve-
sicle or Ago2 complexes was proposed but requires further
elucidation. Notably, Ago2 is not the only miRNA-binding protein
released in the cell culture supernatant. A total of 12 RNA-binding
proteins were identiﬁed by mass spectrometry in the conditioned
medium of human ﬁbroblasts following 2 h of serum starvation,
15
including nucleophosmin (NPM1). Direct binding of NPM1 protected
miRNAs from degradation. The role of the other RNA-binding
proteins is currently unclear, but they had apparently no protective
effect against the degradation of synthetic miR-122, at least in vitro.
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mechanism for intercellular
communication?
Besides their potential as biomarkers, circulating miRNAs may act as a
deliverysystemandcouldplayapreviouslyunrecognizedroleinmodu-
lating cell function. Interaction of exosomes with recipient cells is
thought to arise through receptor-ligand interactions,
48 although
fusion to the plasma membrane of target cells or endocytosis-like in-
ternalization of exosomes has also been observed. In an in vivo model
that enabled close monitoring of miR-16 activity, nude mice were
implanted with cells engineered to express a reporter for the 3′UTR
of B-cell lymphoma 2, a validated target of miR-16. Subsequent intratu-
mourinjectionofexosomesderivedfromHEK293cellsoverexpressing
miR-16 led to suppression of luciferase activity. Control exosomes had
no effect on bioluminescence. These data indicate that exosomal
miR-16 delivered its inhibitory ability on its target gene to the recipient
cells in vivo.
49 Similarly, secreted miR-150 from monocytic cells was
shown to enhance endothelial cell migration. miR-150 is enriched in
leucocytes and lymphocytes, and its presence in microvesicles is
increased following stimulation of cells with proinﬂammatory stimuli.
miR-150 is known to target c-Myb, a transcription factor related to
cell proliferation, lineage commitment, and migration.
50 Delivery of
microvesicles from monocytic cells overexpressing miR-150 down-
regulatedc-Mybinrecipientendothelialcellsandenhancedtheirmigra-
tion. Moreover, increased circulating levels of miR-150 were detected
in patients with severe atherosclerosis. Microvesicles isolated from
thesepatientsinducedasimilarresponseinendothelialcellssupporting
theideaofamiRNAcrosstalkbetweenmonocytesandendothelialcells
indisease.
10 Direct deliveryofmiRNAstorecipientcellscanalsooccur
byHDLthrough aceramidesignalling pathwaydependentmanner. The
miRNAs within HDL altered the cellular miRNA pool and were func-
tional as shown by a loss of corresponding miRNA targets. Thus,
besides the well-established role of HDL for reverse cholesterol trans-
port and as a prognostic marker for cardiovascular disease, its miRNA
content might have biological relevance.
18 Similarly, Ago2 may not just
beacarrierofcirculatingmiRNAs, butthemiRNA–proteincomplexes
could have a functional role in silencing gene regulation in recipient
cells.
17 Although microvesicles and HDL–miRNA complexes were
capable of affecting the expression of target genes in recipient cells
Figure 1 Compartmentalization of circulating miRNAs. Circulating miRNAs are contained within vesicles (exosomes, microparticles, apoptotic
bodies), in protein complexes (Ago2, NPM1) and in lipoprotein complexes (HDL, LDL complexes). Although various tissues contribute to the cir-
culating miRNA pool, most miRNAs are probably derived from blood cells. In response to injury, such as AMI, cardiac-speciﬁc miRNAs, which are
otherwise undetectable are released into the circulation.
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of endogenous extracellular miRNAs in vivo are still missing.
4. Circulating miRNAs as
biomarkers in cardiovascular
diseases
Expression signatures of circulating miRNAs are emerging as novel
biomarkers for cardiovascular disease. The miRNA content in the cir-
culation is likely to reﬂect the activation state of circulating cells and
may provide an integrated read-out of cell activation and tissue injury
in response to cardiovascular risk factors and disease.
4.1 Acute myocardial infarction
4.1.1 miR-1
The putative diagnostic and prognostic value of cardiac miRNAs has
been studied in a rat model of acute myocardial infarction (AMI)
induced by coronary ligation. Levels of circulating miR-1 showed a
strong positive correlation with myocardial infarct size, peaking at
6 h and returning to baseline 3 days post-AMI. Circulating miR-1
was also increased in patients with AMI
51 and positively correlated
to serum creatine kinase-MB (CK-MB).
52 These ﬁndings were corro-
borated in another study, which showed a correlation between
plasma levels of miR-1 and the QRS complex.
53
4.1.2 miR-208
While miR-1 is highly expressed in heart and skeletal muscle, miR-208
expression is supposed to be restricted to the heart. Its circulating
levels were elevated following isoprotenol-induced myocardial injury
in rats.
54 This response was not observed after renal injury, suggesting
that circulating miR-208 is speciﬁc for cardiac injury. As expected,
there was a good association between miR-208 and cardiac troponin
I (cTnI), an established blood marker of AMI
54 supporting the notion
that circulating miRNAs can serve as biomarkers of tissue injury.
14 In
humans, microarray screening identiﬁed miR-208a as being exclusively
expressed in the heart. Indeed, miR-208a was undetectable in healthy
individuals and not affected by injury in other tissues such as acute
kidney injury, chronic renal failure, stroke, and trauma. Instead,
miR-208a displayed both high sensitivity and speciﬁcity for AMI.
55 A
rise in miR-208a was evident within 1–4 h after the onset of chest
pain when cTnI was not yet affected, indicating that miRNAs may
leak into the bloodstream at an earlier stage of myocardial injury
(the biological peak of troponins is  14–18 h after timed AMI).
4.1.3 miR-499
In a separate study, circulating miRNAs were isolated from patients
with AMI, viral myocarditis, diastolic dysfunction, and acute heart
failure (HF). Apart from miR-208b, a signiﬁcant increase in cardiac
myocyte-associated miR-499 was observed in AMI. Both miRNAs
correlated with circulating cardiac troponin T (cTnT), and were mod-
estly elevated in viral myocarditis. Circulating levels of the
leucocyte-expressed miRNAs (miR-146, miR-155, and miR-223)
were similar in patients with AMI or viral myocarditis despite elevated
white blood cell counts. On the other hand, individuals with acute HF
had higher levels of miR-499, whereas levels were unchanged in
diastolic dysfunction.
56
4.1.4 miR-133
Microarray analysis conﬁrmed that miR-1, miR-133a, miR-208a, and
miR-499 were signiﬁcantly reduced in the infarcted myocardium,
while circulating miR-1 and miR-133a were increased in patients
with AMI, suggesting that these miRNAs originate from the injured
myocardium. miRNA proﬁling of plasma samples derived from
patients with AMI revealed increased levels of miR-1, miR-133a,
miR-133b compared with healthy subjects.
51 Intriguingly, other
highly expressed miRNAs in the heart (miR-24, miR-26a, miR-126,
miR-30c) were not affected. To delineate the contribution of the
heart and the skeletal muscle, two animal models were compared:
in a murine model of AMI, miR-1, miR-133a, and miR-133b levels
peaked 6–18 h after coronary occlusion. In contrast, levels of circulat-
ing miR-1, miR-133a, and miR-133b showed an early decline in a
mouse model of hind-limb ischaemia and returned to baseline
within a day.
51
4.2 Acute coronary syndrome
In the largest study on myocardial infarction to date (n ¼ 444), 6
miRNAs (miR-1, miR-133a, miR-133b, miR-208a, miR-208b, and
miR-499) were compared in patients with non-ST-elevation myocar-
dial infarction (NSTEMI), ST-elevation myocardial infarction (STEMI),
and unstable angina.
57 miR-208b was only detectable in NSTEMI and
STEMI patients. Individuals with undetectable miR-208b levels had the
best prognosis. Mortality increased with rising levels of circulating
miR-208b. miR-133a was detectable in all samples, but higher in
patients with NSTEMI or STEMI compared with unstable angina. Cir-
culating concentrations of miR-133a were correlated with all-cause
mortality at 6 months in a non-linear U-shaped relationship. Patients
in the ﬁrst and fourth quantiles of miR-133a had the worst prognosis,
probably due to the inverse association of miR-133a with younger age.
However, multiple regression analysis revealed that miR-208b and
miR-133a were associated with high-sensitivity troponin T (hsTnT).
After adjustment for hsTnT, both miRNAs lost their independent as-
sociation with patient outcome.
4.3 Stable coronary artery disease
miRNA proﬁling suggested that cardiac enriched miR-133a and
miR-208a were higher in patients with stable coronary artery
disease. Additionally, endothelial enriched miR-126 and the cluster
miR-17–92 (miR-17, miR-20a, miR-92a) were down-regulated in
patients, both in the discovery (n ¼ 36) and the validation cohort
(n ¼ 31). Likewise, the inﬂammation-associated miR-155 was signiﬁ-
cantly reduced.
58
4.4 Heart failure
Tijsen et al.
59 assessed the plasma miRNA proﬁle in patients with HF
(n ¼ 50). Healthy controls and patients with other forms of dyspnoea
were used as controls. A total of 16 miRNAs were validated by qPCR
but only 10 of the candidates identiﬁed by the array were differentially
expressed, including miR-423-5p. miR-423-5p emerged as a signiﬁcant
predictor of HF in a multivariate logistic regression model including
age and sex. miR-423-5p distinguished HF cases from healthy controls
and patients within other forms of dyspnoea not related to HF. Con-
cerns, however, were raised regarding the validity of the statistical
analysis and the size of the study population.
60 Clearly, larger clinical
studies are needed to determine the clinical value of miR-423-5p as a
biomarker of HF.
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Screening for circulating miRNAs revealed a novel link between
human cytomegalovirus and essential hypertension.
61 A panel of 27
differentially expressed miRNAs was identiﬁed. Validation of a
subset of putative targets conﬁrmed altered expression of
miR-296-5p, let-7e, and hcmv-miR-UL112, a human
cytomegalovirus-encoded miRNA. Interferon regulatory factor 1
was shown to be a direct target of hcmv-miR-UL112. Seropositivity
and high antibody titres to cytomegalovirus were more common in
hypertensive individuals. Thus, the miRNA proﬁle led to potential
new insights into the pathogenesis of this disease.
61 The role of
miRNAs in secondary hypertension has not yet been explored.
4.6 Type II diabetes
We have recently performed the ﬁrst population-based prospective
study on circulating miRNAs (n ¼ 822). Interestingly, miR-126 was
among the miRNAs most consistently associated with type II diabetes
(DM). When circulating levels of miR-126 were determined in the
entire Bruneck cohort (n ¼ 822, 1995 evaluation), miR-126 was asso-
ciated with current (1995) and subsequent DM (1995–2005) and in-
versely correlated with its severity. In logistic regression analyses,
miR-126 emerged as a signiﬁcant predictor of manifest DM [odds
ratio (95% CI) for a 1-SD unit decrease in loge-transformed expres-
sion level of miR-126, 2.23 (1.69–2.96); P ¼ 2.28 × 10
28] and this as-
sociation persisted in a multivariable model [odds ratio (95% CI), 1.64
(1.19–2.28); P ¼ 0.0027]. Moreover, there was a gradual decrease in
circulating levels of miR-126 across categories of normal glucose tol-
erance (n ¼ 580), impaired fasting glucose/impaired glucose tolerance
(n ¼ 162) and manifest DM (n ¼ 80) (Figure 2). These results from
diabetic patients were corroborated using an animal model of hyper-
glycaemic obese mice (Lep
ob). Endothelial cells constitute a preferred
target of DM-induced damage because they lack a regulated control of
glucose inﬂux. Primary consequences of glucose overload manifest as
endothelial dysfunction, increased vascular permeability and micro-
vascular cell loss by apoptosis. Systemic endothelial dysfunction
alters the production of vasoactive substances and reactive oxygen
species and modiﬁcation of the basement membranes is believed to
play a decisive role in the vascular complications of DM leading to
impaired angiogenesis and collateral vessel development. Indeed,
loss of circulating miR-126 emerged as a positive predictor of subclin-
ical and manifest peripheral artery disease in DM. In detail, miR-126
was associated with a low ankle-brachial index (,0.9, n ¼ 77) [un-
adjusted and age-/sex-adjusted odds ratio (95% CI) for a 1-SD unit de-
crease in loge-transformed expression level of miR-126, 1.95 (1.48–
2.57) P , 0.001 and 1.39 (1.04–1.86) P ¼ 0.025] and with new-onset
symptomatic peripheral artery disease (1995–2005, n ¼ 15) [un-
adjusted and age-/sex-adjusted hazard ratio (95% CI) for a 1-SD
unit decrease in loge-transformed expression level of miR-126, 2.63
(1.38–5.02) P ¼ 0.0032 and 2.15 (1.06–4.38) P ¼ 0.030]. These ﬁnd-
ings suggest that miRNA signatures may have diagnostic and prognos-
tic value in DM,
62 but require validation in independent cohorts. Also,
the mechanism for the loss of miR-126 is currently unclear. In prin-
ciple, changes in circulating miRNAs should be the net effect of
altered secretion, degradation, and cellular uptake. In a model of
hyperglycaemia, endothelial cells cultured in conditions of high
glucose did not show differences in miR-126 expression but exhibited
reduced packaging of miR-126 to ABs.
62 Thus, it is tempting to specu-
late that selective export of miRNAs contributes to the reduced
levels of circulating miR-126. However, further studies are required
to delineate the cellular origin of miR-126 in the circulation and to
clarify whether loss of miR-126 in DM is associated with impaired re-
sponsiveness to VEGF contributing to defects in collateral vessel
development.
63
Adapting a different approach for identifying circulating miRNAs in
DM, Kong et al.
64 explored the expression of miRNAs involved in
insulin biosynthesis and secretion, such as miR-9, miR-29a, miR-30d,
miR34a, miR-124a, miR146a, and miR-375. All seven miRNAs were
signiﬁcantly up-regulated in diabetic patients compared with controls.
Unlike miR-126, no signiﬁcant differences were detected between
subjects with prediabetes and healthy controls suggesting that a rise
in insulin-regulating miRNAs does not precede the development of
the disease. Similarly, increased circulating levels of miR-503 were re-
cently reported in diabetic patients undergoing foot amputation for
critical limb ischaemia (n ¼ 11).
65 While this miRNA may leak into
the plasma in advanced stages of disease, i.e. after muscle necrosis,
it remains unclear whether miR-503 is detectable in patients with
less advanced DM.
66
Figure 2 Circulating levels of miR-126 across categories of normal
glucose tolerance (NGT), impaired fasting glucose/impaired glucose
tolerance (IFG/IGT) and manifest DM. Squares and lines indicate
adjusted geometric means and 95% CIs [white squares: values
adjusted for age and sex and black squares: values adjusted for
age, sex, social status, family history of DM, body mass index,
waist-to-hip ratio, smoking status, alcohol consumption (g/day),
physical activity (sports index) and high-sensitivity C-reactive
protein]. This analysis was performed in the entire study population
(n ¼ 822). Differences in miR-126 between categories of NGT, IFG/
IGT and DM were compared with General Linear Models (GLM) and
P-values are for trend. World Health Organization (WHO) deﬁn-
ition of categories: normal glucose tolerance (fasting glucose , 110
mg/dL and 2 h glucose , 140 mg/dL), impaired fasting glucose/
impaired glucose tolerance (110 mg/dL ≤ fasting glucose , 126
mg/dL, 140 mg/dL ≤ 2 h glucose , 200 mg/dL) and manifest DM.
American Diabetes Association (ADA) deﬁnition of categories:
normal glucose tolerance (fasting glucose , 100 mg/dL and 2 h
glucose , 140 mg/dL), impaired fasting glucose/impaired glucose tol-
erance (100 mg/dL ≤ fasting glucose , 126 mg/dL, 140 mg/dL ≤ 2h
glucose , 200 mg/dL) and manifest DM (reproduced with permis-
sion from Zampetaki et al., Circ Res, 2010
62).
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circulating miRNAs
Statistical analysis of the association between circulating miRNA levels
and disease endpoints faces two major challenges. First, circulating
miRNAs are highly correlated (r ¼ 0.6–0.9) and conventional statis-
tical methods show poor performance when allowing for highly cor-
related variables with the statistical phenomenon of multicollinearity
yielding imprecise, overﬁtted and potentially biased effect estimates.
Second, testing large numbers of miRNAs ( 800 are usually
covered by miRNA arrays) in studies with only small numbers of
cases leads to an increase in the type I error and a high risk of
chance ﬁndings. Beyond the usual standards in high-quality epidemio-
logical research, additional analytical standards are a prerequisite for
circulating miRNA studies.
5.1 Appropriate study design
Studies must be adequately sized and samples for measurement of
miRNAs should be drawn prior to disease manifestation (prospective
design). Comparisons between hospitalized patients and healthy con-
trols, for example, are likely to be confounded by medication and
common cardiovascular risk factors.
5.2 Lack of accepted standards
For any potential clinical application, circulating miRNA measure-
ments have to be performed with high accuracy and precision.
miRNA isolation was initially performed using TRIzol reagent and
thus the extracted RNA was contaminated by phenol residues.
However, recent technical advances led to commercially available
kits that have signiﬁcantly improved the quality of the miRNA prepara-
tions from body ﬂuids. Currently, data normalization is the major
concern. Any pre-analytical variation, i.e. haemolysis, affects miRNA
quantiﬁcation.
67,68 Variations in extraction efﬁciency as well technical
variations in the qPCR-based quantiﬁcation of miRNAs require appro-
priate internal controls. Synthetic exogenous miRNAs derived from C.
elegans can be spiked in,
58 but do not account for differences in
extraction efﬁciency. Owing to the lack of generally accepted
standards, various endogenous miRNAs (miR-17–5p, miR-1249,
miR-454) or small non-coding RNAs (RNU6b) were used for normal-
ization purposes.
7,51,54,59,62 Possible alternatives are the Ct average of
a miRNA panel or the total protein content of microvesicles.
10,18
Different methods should be employed to make sure that ﬁndings
are robust irrespective of the way of standardization. These include
spiking of synthetic miRNAs, standardization to the mean of all
measured miRNAs, and standardization to individual miRNAs that
are detectable at similar levels in all study subjects, not associated
with disease, and positioned outside the main clusters in the
miRNA network.
5.3 Exploration of miRNA co-expression
networks
The complexity of higher organisms is regulated through the coordi-
nated control of biological networks, including miRNAs.
69 Computa-
tional networks have previously been generated using miRNA array
data.
69,70 For the ﬁrst time, we have applied a similar approach to cir-
culating miRNAs
62 (Figure 3). In such networks, nodes represent dis-
tinct miRNAs while edges represent computationally derived
relationships, such as co-expression, between miRNA pairs. A
network-driven analysis offers additional insights compared with
studying up- or down-regulation of individual miRNAs alone. First,
availability of graph clustering algorithms such as Markov clustering
71
allows identiﬁcation of miRNA modules that are likely to be involved
in the same biological process
69 or delineation of proximal miRNA
pairs.
72 Second, integration of differential expression proﬁling with
network topology—contribution of a single miRNA to the stability
of the co-expression network
73—may provide a more reliable alter-
native to target prioritization and subsequent validation.
70 Finally, rep-
resentation of biological data as networks of relationships facilitates
data integration across multiple levels of biological complexity and
may deﬁne contribution of speciﬁc miRNAs to systems-wide proper-
ties of disease.
70 While network biology is a powerful approach for
studying relationships between genes, proteins, and diseases,
74 its ap-
plication in the biomarker ﬁeld is at an early stage and further analyt-
ical and experimental efforts will be needed to substantiate its utility.
Network inference algorithms could be particularly useful to charac-
terize circulating miRNA networks, to unravel rewiring of miRNA
proﬁles under pathological conditions and to test for potential asso-
ciations of miRNA clusters with disease endpoints.
5.4 L1-penalized Cox regression for
high-dimensional and highly correlated data
As mentioned above, common statistical approaches should be com-
plemented by more sophisticated procedures suitable for high-
Figure 3 Circulating miRNA networks. Differential network struc-
ture between 13 miRNAs in controls and manifest DM. Nodes rep-
resent individual miRNAs and edges (links) represent the extent of
expression similarity measured using the Context likelihood of re-
latedness algorithm. For each miRNA topological parameters includ-
ing node degree, clustering coefﬁcient, and eigenvector centrality can
be systematically calculated. Node degree is deﬁned as the total
number of edges that are connected to a given miRNA. Clustering
coefﬁcient is the degree to which miRNAs tend to cluster together.
Eigenvector centrality is a measure of miRNA importance, such that
a particular miRNA receives a greater value if it is strongly correlated
with other miRNAs that are themselves central to the network.
Control (13 nodes, 25 links) and DM (13 nodes, 19 links) networks
shared only 10 links. miR-126 occupied a central position within the
network and the disease state was characterized by substantial edge
rewiring, i.e. for miR-15a (reproduced with permission from Zampe-
taki et al., Circ Res, 2010
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A. Zampetaki et al. 560dimensional and collinear data. We have successfully applied
L1-penalized Cox regression analysis, which was initially developed
to generate gene signatures from micro-array data (package ‘pena-
lized’, freely available).
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5.5 Replication in independent cohorts
Rigorous replication of ﬁndings in independent population samples
and/or experimental animals should be obligatory to minimize the
probability of reporting false-positive ﬁndings.
5.6 Experimental ﬁndings in support
of observed associations
Findings gain persuasiveness if corroborated by appropriate experi-
ments highlighting pathophysiological plausibility for the association
observed or if ﬁndings in patients are replicated in animal models of
disease.
6. Conclusion
There are currently no good soluble biomarkers, which could be used
to accurately identify subjects who are at risk of developing acute
manifestations of cardiovascular disease. Despite extensive studies
and development of several risk prediction models, traditional risk
factors fail to predict cardiovascular events in a large group of cases
(25–50%). Inﬂammatory markers such as high-sensitivity C-reactive
protein are widely used but lack speciﬁcity for the vasculature.
Advanced imaging techniques are expensive and not suitable for
population-wide screening. Besides, atherosclerosis is a diffuse dis-
order with various local and systemic manifestations. Circulating
miRNAs could be attractive biomarkers. They are easily accessible,
relatively stable and in some instances tissue speciﬁc. On the other
hand, the point of care test for cTnI and cTnT can already provide
results within minutes of bleeding the patient. Laboratory-based
assays such as hsTnT are faster than qPCR-based assays, and the
latter will not be of clinical value unless they outperform existing
tests for myocardial injury. However, qPCR-based assays are used
routinely for the diagnosis of viral infections. Undoubtedly, there is
a clinical need for biomarkers of vascular injury that could comple-
ment the assessment of traditional risk factors in monitoring vascular
health and stratifying patients according to risk and treatment
response. It remains to be seen whether miRNAs can fulﬁl this
need and improve risk prediction. At least, circulating miRNAs may
offer new insights into the mechanisms and systemic manifestations
of cardiovascular disease.
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